Abstract
Hyperlipidemia is a primary driver of atherosclerosis and cardiovascular disease. While statins like lovastatin (LOV) are standard clinical treatments, they are often associated with side effects. This study investigates the lipid-lowering potential of Red Yeast Rice (RYR) and Monascus pigments (PIG) fermented by the Monascus strain SHM1105. In a rat model of diet-induced hyperlipidemia, RYR and PIG significantly reduced body weight gain, organ weight ratios, and serum lipid levels (TC, TG, LDL-C). Multi-omics analysis revealed that these natural mixtures modulate the gut microbiota—specifically lowering the Firmicutes/Bacteroidetes ratio—and regulate liver gene expression pathways, including bile acid biosynthesis. These findings suggest that RYR and PIG offer synergistic therapeutic benefits that extend beyond the mechanisms of pure lovastatin.
Introduction
Hyperlipidemia, characterized by elevated blood lipids, is a major risk factor for cardiovascular and cerebrovascular diseases. Although lovastatin is highly effective at inhibiting cholesterol synthesis, its use can be limited by muscle toxicity and liver enzyme elevation. Red Yeast Rice (RYR) is a traditional medicinal food containing natural lovastatin (Monacolin K) and various other bioactive compounds, such as pigments.
While previous research has often focused on isolated components, RYR and its pigments are typically consumed as complex mixtures. This study addresses whether these "natural cocktails" provide synergistic benefits by interacting with the gut-liver axis—the critical biological pathway connecting intestinal bacteria to hepatic metabolism. Using the Monascus strain SHM1105, researchers explored the systemic effects of RYR and PIG on blood lipids, intestinal flora, and the liver transcriptome.
Methods
The study utilized a Sprague-Dawley (SD) rat model induced into a hyperlipidemic state via a high-fat, high-sugar (HFS) diet. Five experimental groups were compared: a normal control (CK), the HFS model, and three treatment groups receiving either Lovastatin (LOV), Red Yeast Rice (RYR), or Monascus Pigment (PIG).
A multi-omics approach was employed to map systemic changes:
- 16S rRNA Sequencing: To profile the gut bacterial community.
- RNA-Seq (Transcriptomics): To measure gene expression changes in the liver.
- UHPLC-QTOF-MS (Metabolomics): To identify shifts in liver metabolites.
- Bioinformatics Integration: Correlating gut microbial shifts with liver metabolic pathways to elucidate the mechanism of action.
Results and Discussion
Physiological Impact and Organ Health
Intervention with LOV, RYR, and PIG significantly mitigated the physiological damage caused by the HFS diet. As illustrated in Figure 1, the HFS group showed marked increases in body weight growth and the weight ratios of the liver, kidney, spleen, and adipose tissues. Treatment with RYR and PIG significantly reversed these trends (p < 0.05). Notably, the PIG group demonstrated a 24.64% reduction in weight growth rate compared to the HFS group, highlighting the potent metabolic regulatory capacity of Monascus pigments.
Lipid Profiles and Microbiota Shifts
Both RYR and PIG interventions effectively lowered serum Total Cholesterol (TC), Triglycerides (TG), and Low-Density Lipoprotein Cholesterol (LDL-C). PIG treatment was particularly effective, reducing TC by 30.8% and TG by 47.44%, outperforming the LOV group in these specific metrics.
Microbiota analysis revealed that the HFS diet spiked the Firmicutes/Bacteroidetes (F/B) ratio, a hallmark of metabolic syndrome. All treatments significantly lowered this ratio (p ≤ 0.01), effectively "resetting" the gut environment. There was a notable increase in the abundance of the Bacteroidales-S24-7-group, which is associated with reduced obesity, and a decrease in Lactobacillaceae.
Synergistic Gene Regulation
Transcriptomic data indicated that while lovastatin primarily targets HMG-CoA reductase, RYR and PIG influence a broader array of pathways. Both mixtures down-regulated the LPIN gene, inhibiting triglyceride synthesis. Uniquely, the PIG group up-regulated the CYP7A1 gene, which promotes the conversion of cholesterol into bile acids for excretion. This "drainage" mechanism for excess cholesterol provides a therapeutic pathway that pure lovastatin does not utilize as effectively.
Conclusion
The study concludes that RYR and PIG fermented by Monascus SHM1105 are effective in reducing lipid potential. By utilizing multiple, synergistic pathways—including bile acid secretion and the modulation of the gut-liver axis—these natural mixtures represent a promising foundation for new functional foods and alternatives to traditional statin therapy.
Data Availability: Microbial sequencing data is deposited in the NCBI SRA under Accession Number PRJNA670295.
Summary updated